Apollomics (APLM) Preferred Stock Liabilities (2021 - 2023)
Apollomics (APLM) posted quarterly Preferred Stock Liabilities of -$76.4 million for Q4 2023, up 59.7% year-on-year from -$47.9 million in Q4 2022, and little changed on a QoQ basis from -$76.4 million in Q2 2023.
Apollomics (APLM) Preferred Stock Liabilities (2021 - 2023) Analysis & Trends
Apollomics (APLM) has reported Preferred Stock Liabilities for 3 consecutive years, with -$76.4 million the latest figure, recorded in Q4 2023.
- Quarterly Preferred Stock Liabilities rose 59.7% year-over-year to -$76.4 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$76.4 million (up 59.7% YoY) and the FY2023 annual result came in at -$76.4 million, down 114.93% from the prior year.
- Preferred Stock Liabilities was little changed at -$76.4 million in Q4 2023 per APLM's latest filing, from -$76.4 million in the prior quarter.
- Over the last five years, Preferred Stock Liabilities for APLM reached as high as $23.7 million in Q2 2022 and fell as low as -$189.6 million in Q4 2022.
- A 3-year average of -$71.3 million and a median of -$76.4 million in 2023 frame the typical range for Preferred Stock Liabilities.
- The largest YoY upside for Preferred Stock Liabilities was 59.7% in 2023 against a maximum downside of 422.91% in 2023.
- Year by year, Preferred Stock Liabilities stood at -$37.4 million in 2021, then sank by 406.75% to -$189.6 million in 2022, then surged by 59.7% to -$76.4 million in 2023.
- According to Business Quant data, Preferred Stock Liabilities over the past three periods registered -$76.4 million, -$76.4 million, and -$189.6 million for Q4 2023, Q2 2023, and Q4 2022 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Apollomics | 2.66 Bn | 2.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -76.43 Mn |
| Jun 30, 2023 | -76.43 Mn |
| Dec 31, 2022 | -189.65 Mn |
| Jun 30, 2022 | 23.67 Mn |
| Dec 31, 2021 | -37.42 Mn |